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Ghrelin is a 28-amino-acid peptide that displays a strong growth hormone- (GH-) releasing activity through the activation of the
growth hormone secretagogue receptor (GHSR). The first studies about role of ghrelin were focused on its orexigenic ability, but
despite indisputable pharmacological data, the evidence for a physiological role for ghrelin in the control of appetite is much less
clear. Mice with targeted deletion of either ghrelin or the GHSR exhibit an essentially normal metabolic phenotype when fed a
regular chow diet, suggesting that ghrelin may have a redundant role in the regulation of food intake. RNAs for ghrelin as well as
GHSR are expressed in the pancreas of rats and humans and several studies propose that ghrelin could have an important function
in glucose homeostasis and insulin release, independent of GH secretion. Low plasma ghrelin levels are associated with elevated
fasting insulin levels and insulin resistance, suggesting both physiological and pathophysiological roles for ghrelin. For this reason,
at least theoretically, ghrelin and/or its signalling manipulation could be useful for the treatment or prevention of diseases of
glucose homeostasis such as type 2 diabetes.
1. Introduction
GH is released from the pituitary gland in a pulsatile
manner and it is mainly regulated by episodic changes
in two hypothalamic hormones, growth hormone-releasing
hormone (GHRH) and somatostatin. GHRH stimulates GH
secretion whereas that somatostatin inhibits it [1]. In 1976,
it was revealed that modified opioid peptides had low GH
secretory activity [2]. Since then, many eﬀorts have been
made to develop and improve potential applications of
these GH secretagogues (GHSs) [3–7]. GHSs act on the
pituitary and hypothalamus to release GH, not through the
growth hormone releasing hormone receptor (GHRHR) but
through an orphan receptor, the GHSR [8]. These facts
indicated that an unknown endogenous ligand for GHSR
should exist. In 1999, ghrelin was identified as the endoge-
nous ligand for the GHSR. It is a 28-amino-acid peptide
predominantly produced by the stomach that functions as
a somatotrophic and orexigenic signal from the stomach
[9, 10]. Ghrelin is most abundantly expressed in specialized
cells in the oxyntic glands of the gastric epithelium, originally
termed X/A-like cells [11]. Approximately 60%–70% of
circulating ghrelin is secreted by the stomach, and most of
the remainder originates in the small intestine [11]. Nev-
ertheless low-level ghrelin expression also occurs in several
tissues outside the gut, including hypothalamus (arcuate
nucleus and paraventricular nucleus), pituitary, lung, adrenal
cortex, kidney, bone, testis, placenta, and pancreatic islet
cells [12]. The GHSR mRNA is expressed as two splice
variants encoding the cognate receptor GHSR1a and the
apparently nonfunctional receptor GHSR1b [13]. GHSR1a
signals via inositol trisphosphate (IP3) generation and Ca2+
release and has constitutive activity [13, 14]. GHSR1b mRNA
is as widely expressed as ghrelin, whereas GHSR1a gene
expression is concentrated in the hypothalamus-pituitary
unit, although it is also distributed in other central and
peripheral tissues [15]. Ghrelin circulates in the bloodstream
in two diﬀerent forms: acylated (or n-octanoylated, AG) and
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unacylated (or des-octanoylated or des-acylated, UAG) [9].
AG has a unique feature: a posttranslational esterification
of a fatty (n-octanoic or, to a lesser extent, n-decanoic)
acid on serine residue at position 3 [9]. Recent data showed
that Ghrelin O-acyltransferase (GOAT), a membrane-bound
enzyme, is responsible for octanoylation of the serine-3
residue of ghrelin [16, 17]. Ghrelin acylation is considered
necessary for its actions via GHSR1a, such as its strong GH-
releasing activity [9, 18–20]. Normally AG accounts for less
than 10% of the total ghrelin in the circulation. The majority
of circulating ghrelin is UAG, which does not have eﬀects in
GH release, but it is not biologically inactive [19, 21–29]. It
binds with high aﬃnity to a receptor, diﬀerent from GHSR1a
and yet unknown [9, 12]. The first studies about ghrelin
demonstrated that it increases food intake and adiposity
[10]. Moreover, plasma ghrelin levels have been shown to
increase prior a meal and during fasting and to decrease after
a meal, and they are negatively correlated with body weight
[30–32]. All these data suggested a role in the control of
energy homeostasis. But the conflicting food intake and body
weight data from transgenic and knockout models, which
present normal metabolic phenotype, has made diﬃcult
defining a key role for endogenous ghrelin in the control
of appetite [27, 33–39]. Nevertheless, the data consistently
suggest that ghrelin may be important in the control of
glucose homeostasis and insulin release.
It was reported that prolonged treatment with GHSs
provoked hyperglycemia and hyperinsulinism but this eﬀect
was supposed to reflect increased GH secretion [40–43], as
GH plays an important role modulating energy homeostasis
and metabolism [44]. Particularly, GH exerts both acute
and chronic eﬀects on carbohydrate and lipid metabolism
[44]. Interestingly, both actions display an opposite pattern,
with acute eﬀects showing a transient “insulin-like” action
and chronic eﬀects exhibiting an “anti-insulin” action.
In this sense, GH administration decreases blood glucose
concentration, stimulates glucose uptake by skeletal muscle,
and stimulates glucose transport and lipogenesis in isolated
adipocyte [44, 45]. However these eﬀects are transitory; after
a few hours the chronic anti-insulin eﬀects of GH arise,
increase blood glucose concentration, insulin resistance,
stimulation of lypolysis, and inhibition of glucose transport.
High plasma GH levels induce hyperinsulinemia and insulin
resistance [12, 46]. On the other hand, besides its lipolytic
action, GH exhibit antilipogenic eﬀects [47, 48] promoting
proliferation of lean tissues, while reducing accumulation of
fat tissue. Accordingly, GH-deficient states in humans and
rodents are characterized by a decrease in lean body mass
accompanied by increased adipose tissue [49–53].
Early studies demonstrated that RNAs for ghrelin, as well
as GHSR, are expressed in the pancreas of rats and humans
[9, 15, 54, 55] and β-cells lines [56, 57] suggesting a possible
relation between ghrelin and insulin. Studies using diﬀerent
experimental systems localized ghrelin-immunoreactive cells
in rat and human pancreas in the α-cells [54, 57, 58],
β-cells [55], PP-cells [57], and other islets cells [57, 59],
including those named ε-cells [60]. The first evidences about
an interaction between ghrelin and glucose metabolism arose
when it was seen that single subcutaneous ghrelin injections
induced an increase of the respiratory quotient (RQ), which
suggested an augmented utilization of carbohydrate and
reduced utilization of fat to meet energy requirements that
was congruent with the observed increase in body fat [10].
Another evidence that suggested that ghrelin could aﬀect
glucose metabolism was the fact that it stimulated acid
secretion through vagal mediation [61, 62] and some studies
suggested that the parasympathetic nerves that regulate
hormonal control of insulin pass through the cervical
vagus and the hepatic branch, and that the hepatic vagus
nerve is important for the regulation of hepatic glucose
production in the post absorptive state [63, 64]. All these
data and numerous studies since 2000 to the present time
suggest that ghrelin has an important role in regulating β-
cell function and glucose homeostasis. Indeed, the weight
of evidences could support even a more physiologically
important function in the control of glucose homeostasis
than appetite regulation.
In this work we will review the results obtained by
diﬀerent investigators about the relation between ghrelin and
glucose metabolism and insulin release as well as its possible
therapeutic role in disease states like diabetes.
2. Effects of Exogenous Ghrelin on
Glucose and Insulin Levels
2.1. Short-Term Eﬀects. The first studies with ghrelin showed
that acute ghrelin treatment induced hyperglycemia and
reduced insulin secretion in healthy humans [65] during
the first hours of treatment. The time course of glucose
modifications occurred with a peak observed before any
significant insulin decreased. Subsequently, these findings
were confirmed by other authors in human and rodents
[58, 66–71]. However, when these experiments were carried
out in obese patients, there was no diﬀerence in glucose
or insulin levels following ghrelin administration [72]. The
first hypothesis suggested that ghrelin itself could have a
direct eﬀect on glucose metabolism, regulating hepatic glu-
cose output, promoting glycogen breakdown, or decreasing
peripheral glucose uptake; consistent with this view were
the findings that ghrelin receptors are expressed in normal
human liver [73, 74].
In order to discard a secondary eﬀect due to increased
GH secretion, human subjects were treated with a GH
receptor blockade, pegvisomant [43], and in this situa-
tion a ghrelin mimetic induced increases in glucose and
insulin levels. Suggesting ghrelin mimetic-mediate GH-
independent insulin resistance, moreover several studies have
demonstrated that interference with ghrelin signalling by
use of GHSR antagonist decreases blood glucose in wild-
type mice as well as GH-deficient lit/lit mice [58, 75]. To
diminish the influence of GH, Vestergaard et al. investigate
the eﬀects of prolonged ghrelin infusion (not a unique
dose) on insulin sensitivity [76] which decreased after few
minutes of ghrelin infusion and outlasted both the infusion
period and the postinfusion interval. As the reduced insulin
sensitivity remained after normalization of both GH and
glucose levels, this work supports that ghrelin eﬀect was
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caused by the ghrelin infusion per se [77]. In a posterior
work the same investigators studied, for the first time, the
concomitant eﬀects of exogenous ghrelin and a pancreatic
clamp on glucose metabolism in humans; they used a
prolonged ghrelin infusion in addition to a somatostatin
infusion to avoid GH secretion. Ghrelin infusion decreased
basal as well as insulin stimulated glucose disposal and
induced peripheral insulin resistance but did not aﬀect
hepatic glucose production [71]. When they studied the
eﬀect of exogenous ghrelin in hypopituitary men (in the
absence of GH and cortisol secretion), in a randomized
double-blind, cross-over design, ghrelin treatment acutely
decreased peripheral, but not hepatic, insulin sensitivity
independently of GH and cortisol [78].
There are data that suggest a relation between ghrelin
and glucose-stimulated insulin secretion (GSIS) via the
hepatic portal system and the vagus nerve. Gastrectomy
and truncal vagotomy are operations characterized by
hypoghrelinemia [30], glucose intolerance as a result of
hyperglucagonemia, insulinopenia, and impaired first phase
of insulin secretion [79]. When ghrelin was infused into
the portal vein of rats, inhibited glucose-stimulated release
of insulin, however when it was infused into the femoral
vein, did not induce such an inhibitory eﬀect. All the
more hepatic vagotomy or coinfusion with atropine methyl
bromide (a muscarinic antagonist) diminished the inhibitory
eﬀect of ghrelin on glucose-stimulated insulin secretion
[70]. Damjanovic et al. also performed studies with ghrelin
and truncal vagotomy, investigating the eﬀects of intra-
venous (IV) ghrelin infusion on insulin-mediated glucose
disposal during a hyperinsulinemic-euglycemic clamp in
humans who underwent total gastrectomy and truncal
vagotomy [80]. In these patients glucose disposal rate (GDR)
decreased during ghrelin infusion; however this diﬀerence
was not translated into a significant diﬀerence in insulin
concentration, probably because the exogenous insulin by
far overweighs endogenous insulin. Thus, there cannot be
ruled the possibility that diminished glucose utilization after
ghrelin administration is partly explained by the decrease in
endogenous insulin secretion, although this was not detected
in the study [80]. It appears that acute ghrelin administration
might be involved in the negative control of insulin secretion
and glucose consumption in gastrectomized patients [80].
In summary, short-term eﬀects of exogenous ghre-
lin induces hyperglycaemia and hypoinsulinism in health
humans and rodents in a GH independent fashion.
In Table 1 are summarized the results obtained after acute
ghrelin treatment in several models and situations.
2.2. Long-Term Eﬀects. Generally long-term ghrelin treat-
ment induced an increase in plasmatic values of glucose,
whereas plasmatic insulin levels, unlike short-term eﬀects,
did not change or enhanced after ghrelin treatment. But
long-term eﬀects of exogenous ghrelin on glucose and
insulin levels are not conclusive; there are diﬀerences inter-
experiments which could reflect diﬀerent doses, administra-
tion way, and/or species used. In long term studies essentially
there are two way of administration: those in which the
administration of ghrelin was systemic: intraperitoneal (IP)
or subcutaneous (SC), and central: when the hormone was
administered directly in a cerebral region.
2.2.1. Systemic Administration. Involves treated IP with ghre-
lin during 4 days, plasma glucose concentrations increased.
At the same time, the authors measured body glycogen stores
and observed that liver glycogen content was unaﬀected, but
the quadriceps muscle and kidney glycogen stores decreased,
indicating them as the possible source of elevated plasma
glucose levels [69]. Similar results were obtained by Asakawa
et al. with mice; they examined the eﬀects of repeated
administration of IP ghrelin on glycaemic control under a
high fat diet (HFD). In these conditions insulin levels were
increased by the treatment and blood glucose concentration
displayed a moderate increase but did not reach statistical
significance [75].
When Barazzoni et al. administrated subcutaneous
ghrelin during four days to normal rats, they found
hyperglycemia; nevertheless plasma insulin levels did not
change [85, 86]. The treatment increased transcript levels
of the key enzyme of the gluconeogenic pathway, glucose-6-
phosphatase (G6Pase) in liver. For these reasons the authors
suggested that enhanced gluconeogenesis in liver would
contribute to increase circulating glucose in ghrelin-treated
animals [85].
2.2.2. Central Administration. In others studies the ani-
mals received ghrelin treatment intracerebroventricularly
(ICV). 6-day ICV ghrelin infusion provoked an increase
on insulin-stimulated glucose utilization during euglycemic-
hyperinsulinemic clamps in epididymal and inguinal white
adipose tissue (WAT) as well as brown adipose tissue
(BAT), but not in soleus muscle. During the clamps, hepatic
glucose production was comparably suppressed by hyper-
insulinemia in all groups. The treatment did not change
plasma glucose or insulin levels [87]. Comparable results
were obtained by Kamegai et al. administering repeated
injections of ghrelin into the lateral ventricle of rats during
72 hours, without changes in plasma glucose and insulin
concentrations, although there was a trend toward higher
levels [88]. However, in another study, ICV ghrelin injections
every 24 hours during five days to adult male rats clearly
increased serum insulin levels without evoking changes in
blood glucose levels [89].
Although the results obtained by ghrelin treatment in the
long term are not enough clear, it seems to exist a tendency
toward an increase in both plasma glucose and insulin levels.
These data could indicate a role for ghrelin in worsening
insulin sensitivity.
In Table 2 are summarized the results obtained in plasma
glucose and insulin levels after prolonged treatment with
ghrelin.
2.3. Studies In Vitro and Perfusion. Besides the experiments
carry out in vivo, there are works with cellular cultures and
pancreatic perfusion that contribute to our knowledge about
ghrelin role on glucose and insulin metabolism, pointing to
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Table 1: Acute eﬀects of ghrelin administration on glucose-insulin homeostasis in diﬀerent species and metabolic situations. IV: intravenous;
O: oral.
Species Treatment Dose
Food before
experiment
Treatment
duration
Plasma
glucose or
GIR
Plasma
insulin
Reference
Health humans
1 IV AG injection
versus 1 IV placebo
injection
1 μg AG/kg
Fasting
overnight
3 hours Enhanced Decreased [65]
Health humans
1 IV AG injection
versus 1 IV placebo
injection
3.3 μg AG/kg
Fasting
overnight
3 hours Enhanced Decreased [68]
Health humans
1 IV AG injection
versus 1 IV placebo
injection
1 μg AG/kg
Fasting
overnight
2 hours Enhanced Decreased [67, 81]
Health humans
1 IV AG injection +
O-GTT versus
O-GTT
1 μg AG/kg +
100 g glucose
Fasting
overnight
2 hours Not change Not change
[81]
1 IV AG injection +
FFA versus FFA
1 μg AG/kg +
10% FFA
Fasting
overnight
2 hours Not change Decreased
1 IV AG injection +
arginine versus
arginine
1 μg AG/kg +
0.5 g arginine/kg
Fasting
overnight
2 hours Enhanced Decreased
Health humans
1 IV AG injection
versus 1 IV placebo
injection
1 μg AG/kg
Fasting
overnight
2 hours Enhanced Decreased
[67]
1 IV UAG injection
versus 1 IV placebo
injection
1 μg UAG/kg
Fasting
overnight
2 hours Not change Not change
1 IV AG injection +
UAG versus 1 IV
placebo injection
1 μg AG/kg +
1 μg UAG/kg
Fasting
overnight
2 hours Not change Not change
Health humans
IV AG infusion
versus IV placebo
infusion
5 pmol
AG/kg/min
Fasting
overnight
3 hours Enhanced Enhanced [77]
Health humans
IV AG infusion
versus IV placebo
infusion
Both with pancreatic
clamp +
hyperinsulinemic-
euglicemic clamp +
glucose adjustable
5 pmol
AG/kg/min
Fasting
overnight
5 hours
During
clamp GIR
diminished
with ghrelin
Not change [71]
Hypopituitary
humans
1 IV AG or UAG
injection versus 1 IV
placebo injection
1 μg AG or
UAG/kg
Fasting
overnight
2 hours Enhanced Not change
[82]
1 IV AG + UAG
injection versus 1 IV
placebo injection
1 μg AG/kg +
1 μg UAG/kg
Fasting
overnight
2 hours Not change Diminished
Hypopituitary
humans
IV AG infusion
versus IV placebo
infusion
Both with
hyperinsulinemic-
euglicemic
clamp
5 pmol
AG/kg/min
Fasting
overnight
5 hours
Basal period
enhanced,
during clamp
GIR
diminished
Not change [78]
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Table 1: Continued.
Species Treatment Dose
Food before
experiment
Treatment
duration
Plasma
glucose or
GIR
Plasma
insulin
Reference
Gastrectomized
humans
IV AG infusion
versus IV placebo
infusion
Both with
hyperinsulinemic-
euglycemic
clamp
5 pmol
AG/kg/min
Fasting
overnight
5 hours
Diminished
GIR
Not change [80]
IV AG infusion
versus IV placebo
infusion
Both with IV-GTT
infusion
1 ng AG/kg/h +
13.3 mg
glucose/kg/min
24-hour
fasting
40 minutes Not change Not change
Normal rats
IP AG infusion
versus IV placebo
infusion
Both with IV-GTT
infusion
1 ng AG/kg/h +
13.3 mg
glucose/kg/min
24-hour
fasting
40 minutes Enhanced Diminished
[70]
IV AG infusion
versus IP placebo
infusion
Both with IP-GTT
infusion
1 ng AG/kg/h +
13.3 mg
glucose/kg/min
24-hour
fasting
40 minutes Not change Not change
IP AG infusion
versus IP placebo
infusion
Both with IP-GTT
infusion
1 ng AG/kg/h +
13.3 mg
glucose/kg/min
24-hour
fasting
40 minutes Enhanced Diminished
Normal rats
1 IV UAG injection
+ IV-GTT versus
IV-GTT
30 nmol
UAG/kg + 1 g
glucose/kg
Fasting
overnight
50 minutes Not change Enhanced
[83]
1 IV AG injection +
IV-GTT versus
IV-GTT
30 nmol
UAG/kg + 1 g
glucose/kg
Fasting
overnight
50 minutes Not change Not change
Rats with
hepatic
vagotomy
IP AG infusion
versus IP placebo
infusion
Both with IP-GTT
infusion
1 ng AG/kg//h
+13.3 mg
glucose/kg/min
24-hour
fasting
40 minutes Not change Not change [70]
Mice ddY
1 IP AG injection
versus 1 IP placebo
injection
Both with IP-GTT
1 and 10 nmol
AG/kg + 1 g
glucose/kg
Fasting
overnight
2 hours Enhanced Decreased
[58]
1 IP AG injection
versus 1 IP placebo
injection
1 nmol/kg
Fasting
overnight
2 hours Enhanced
C57BL/6J mice
1 IV AG injection +
IV-GTT versus
IV-GTT
50 nmol AG/kg
+ 1g/kg
3-hour
fasting
50 minutes Not change Diminished [84]
GH-deficient
little mice
1 IP AG injection
versus 1 IP placebo
injection
1 nmol AG/kg
Fasting
overnight
30 minutes Enhanced [58]
Obese humans
1 IV AG injection
versus IV placebo
injection
1 μg AG/kg
Fasting
overnight
2 hours Not change Not change [72]
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Table 2: Chronic eﬀects of ghrelin administration on glucose-insulin homeostasis in diﬀerent species.
Species
Treatment
administration
Dose
Food during
experiment
Duration
treatment
Plasma glucose
levels
Plasma insulin
levels
Reference
Mice ddy
1 IP AG
injection/12-h
3 nmoles AG/
mouse/injection
Ad libitum HFD 5-day Not change Enhanced [75]
Tundra vole
1 IP AG
injection/day
10 μg AG/kg/day Ad libitum SCD 4-day Enhanced [69]
Sprague-
Dawley
rats
1 ICV AG
injection/12-h
1 μg
AG/rat/injection
Ad libitum SCD 3-day Not change Not change [88]
Wistar rats
1 ICV ghrelin
injection/day
1 μg AG/rat/day Ad libitum SCD 5-day Not change Enhanced [89]
ICV ghrelin
infusion
2.5 nmol
AG/rat/day
Ad libitum SCD 6-day Not change Not change [87]
1 SC AG
injection/12-h
0.2 ug
AG/injection
Ad libitum SCD 4-day Enhanced Not change [85]
a role for ghrelin in the pancreatic islet. The perfused rat pan-
creas is a suitable model to characterize the pancreatic hor-
mone secretory pattern elicited by ghrelin in the short term.
Egido et al. dissected and perfused in situ the pancreas of rats
fed ad libitum; the addition of ghrelin to the perfusate did
not significantly modify basal insulin release but markedly
inhibited the insulin response to increasing glucose concen-
trations, arginine, and carbachol [90]. It was observed that
the glucose-induced insulin release from the rat-perfused
pancreas was markedly enhanced by blockade of GHSR and
immunoneutralization of endogenous ghrelin. Furthermore,
GHSR blockade increased plasma insulin concentrations in
gastrectomized and normal rats to a similar extent [91].
The results obtained with perfused rat pancreas support a
role for ghrelin inhibiting insulin release. These results were
confirmed in studies with isolated islets from normal rats
[58, 92] and MIN 6 cells [93], where ghrelin inhibited the
insulin response to increasing glucose concentrations. But
when ghrelin was coincubated with GHSR antagonists or
antiserum against acylated ghrelin, this eﬀect was blocked
[58, 92]. Moreover, in islets from ghrelin-null mice, glucose
treatment enhanced insulin release [91]. On the contrary,
in another study, it was observed that ghrelin (1 pmol/l)
stimulated insulin release and increased [Ca2+] in rat islet β-
cells in the presence of a stimulatory (8.3 mmol/l) but not
basal (2.8 mmol/l) glucose concentration [54]. However, the
same authors, in a subsequent study, examined the dose-
dependent eﬀects of ghrelin and they found that ghrelin
at 1 pmol/l and 0.1 nmol/l modestly potentiated glucose-
induced [Ca2+]i responses in a little portion of β-cells, but
it failed to significantly alter insulin release. This observation
that ghrelin is inhibitory at relatively high concentrations of
10 nmol/l, while having little eﬀect at lower concentrations,
is consistent with the majority of other reports [58].
Several cell culture studies showed a genetic link between
ghrelin and insulin. The Nkx2.2 hoursomeodomain tran-
scription factor is required for islet cell development and
diﬀerentiation. In this way high levels of Nkx2.2 are necessary
to specify or maintain the islet β cell fate [94]. Nkx2.2
null mice completely lack insulin-producing β-cells and have
reduced numbers of α-cells. In normal islets, a population
of glucagon-expressing α-cells coexpress ghrelin, but approx-
imately two-thirds of ghrelin-expressing cells define a new
endocrine islet, ε cell population. In addition, in the Nkx2.2
mutant islet, the ghrelin-producing ε cell population has
been drastically expanded at the expense of insulin- and
glucagon-producing cells. [60]. Similar to the wild-type islet,
ghrelin producing cells in the Nkx2.2 mutant embryonic
mouse islets do not coexpress insulin, somatostatin, or PP.
However, unlike its expression in wild-type islets, none of
the ghrelin-producing cells in the Nkx2.2 mutant coexpress
glucagon [60].
On the other hand, insulinoma-associated protein (IA)-
2β is a β-cell autoantigen for type 1 diabetes. It is localized
in secretory granules in pancreatic β-cells or neuroendocrine
cells [95]. Stable overexpression of IA-2β inhibited GSIS in
MIN6 cells when performed in medium containing glucose.
Doi et al. observed that ghrelin inhibits GSIS in MIN6 cells
and that the concentrations of ghrelin inhibiting GSIS were
very close to those of ghrelin enhancing IA-2β expression,
suggesting that ghrelin may inhibit GSIS via enhancement
of IA-2β expression [93]. Incubation of cultured MIN6
cells with increasing doses/times of ghrelin showed that
ghrelin induced IA-2β RNA and protein expression dose
dependently. The blockage of IA-2β expression with siRNA
provoked that the inhibitory eﬀects of ghrelin or overexpres-
sion of IA-2β on GSIS were ameliorated, providing direct
evidence of the links between ghrelin, IA-2β, and GSIS;
changes in insulin content in the cell lysates or in insulin
mRNA expression were not observed. [93].
Some of the results obtained with this type of techniques
are displayed in Table 3.
2.4. Unacylated Ghrelin. Acylated ghrelin accounts for less
than 10% of the total ghrelin; the majority of circulating
ghrelin is unacylated. Although UAG does not possess GH
releasing activity, it is not biologically inactive. Several
studies demonstrated a clear metabolic role for UAG; it
is able to share with ghrelin antiproliferative eﬀects on
human breast and prostate cancer lines [97, 98], has negative
inotropic eﬀects on papillary muscle [99], and can stimulate
bone marrow adipogenesis [28]. These eﬀects of UAG could
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Table 3: Results obtained with cellular cultures and pancreatic perfusion that contribute to data about ghrelin role on glucose and insulin
metabolism.
Cellular
type/Perfusion
Treatment Dose Insulin release Glucose output Reference
Islets from normal
rats
AG + glucose
versus glucose
10−12M AG +
2.8 mM glucose
Not change
[54]
AG + glucose
versus glucose
10−12M AG +
8.3 mM glucose
Enhanced
Islets from normal
rats
AG + glucose
versus glucose
10−8M AG +
2.8 mM glucose
Not change
[58]
AG + glucose
versus glucose
10−8M AG +
8.3 mM glucose
Diminished
Islets from normal
rats
AG + glucose
versus glucose
10 nM AG +
20 mM glucose
Diminished
[92]UAG + glucose
versus glucose
1 μM + 20 mM
glucose
Not change
AG + glucose +
YIL-781 versus
glucose
10 nM AG +
20 mM glucose
+ 1 μM YIL-781
Not change
Glucose +
YIL-781 versus
glucose
20 mM glucose
+ 1 μM YIL-781
Not change
Islets from normal
rats
GHRP-6 versus
placebo
1 μM GHRP-6 Enhanced
[58]
SPA versus
placebo
1 μM SPA Enhanced
Ghrelin KO mouse
islets
Glucose ghrelin
KO versus
glucose wildtype
8.3 mM and
16.7 mM
glucose
Enhanced [91]
Min 6 cells
AG + glucose
versus glucose
1–10 nM AG +
22.2 mM
glucose
Diminished [93]
Hepatocytes from
pigs
AG versus
placebo
100 nM AG Enhanced
[96]UAG versus
placebo
100 nM UAG Diminished
UAG + AG
versus AG
100 nM AG +
100 nM UAG
Diminished
Pancreas of rat
perfused in situ
Ghrelin +
glucose versus
glucose
10 nM ghrelin +
5.5 mM glucose
Not change
[90]
Ghrelin +
glucose versus
glucose
10 nM ghrelin +
9 mM glucose
Diminished
Pancreas of rat
perfused in vitro
Ghrelin +
glucose versus
glucose
10 nM ghrelin +
8,3 mM glucose
Diminished
[91]GHRP-6 +
glucose versus
glucose
1 μM GHRP-6 +
8.3 mM glucose
Enhanced
UAG + glucose
versus glucose
10 nmol/l UAG
+ 8.3 mM
glucose
Not change
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not be antagonized by administration of synthetic GHSR1a
antagonists [28] as UAG is unable to bind the classical
GHSR1a, which recognizes ghrelin in its acylated form only
[9]. The signal transduction mechanism(s) for eﬀects of
UAG has not been determined. Evidences that UAG is an
active peptide implies the existence of GHSR subtypes that
recognize and bind ghrelin independently of its acylation.
These binding sites have already been demonstrated in
the cardiovascular system and in the pancreas [21, 98,
100]. Besides the eﬀects above mentioned, several studies
suggested a role of UAG on glucose metabolism. Broglio
and colleagues suggested that ghrelin could have a dualistic
eﬀect on glucose homeostasis; its eﬀect on insulin secretion
and sensitivity could depend on its state of acylation. They
observed that in healthy humans, the administration of UAG
alone did not induce any change in glucose and insulin
levels compared to placebo. Nevertheless UAG counteracts
the eﬀects of AG on glucose and insulin levels, but not its
stimulatory action on GH, PRL, ACTH, and cortisol levels,
indicating that UAG has metabolic impact, being able to
antagonize the eﬀects of AG on insulin and glucose levels,
while it is really inactive from the neuroendocrine point of
view [67].
Similar results were obtained in humans with pituitary
insuﬃciency. In these patients both AG and UAG imme-
diately increase glucose and insulin levels, when AG and
UAG were injected together; this combination prevents the
acute hyperglycaemic and hyperinsulinemic eﬀects of AG
and UAG when injected alone. Moreover, this combination
of AG and UAG improves insulin sensitivity for many hours
when compared with placebo administration and even more
markedly with the aggravation of insulin sensitivity of AG
administration [82].
As both AG and UAG are secreted into the portal
circulation before they reach the systemic circulation, and
the above reported eﬀects of AG and UAG on glucose and
insulin levels in vivo are based on measurements of systemic
blood samples. Gauna et al. hypothesized that, concerning
insulin secretion, assessment of insulin concentration in the
portal vein might be more informative than that in the
systemic circulation. They demonstred in anesthetized rats
that UAG acted as a secretagogue of insulin in the portal
vein. Moreover, this UAG-induced increase in insulin levels
was abolished by the coadministration of AG. This study
showed that UAG potently and dose-dependently enhances
the insulin response to an intravenous glucose load in vivo
[83]. This insulin secretagogue eﬀect of UAG was marked
in the portal vein, whereas it was scarcely detectable in the
systemic circulation, suggesting that UAG plays an important
role in glucose metabolism in the liver. Gauna et al. estimated
that UAG slightly increased the fraction of insulin cleared
by the liver, thus contributing to the augmentation of
the portal-peripheral gradient of insulin [83]. Furthermore
several studies support the possibility that ghrelin has a
direct peripheral action on liver [73, 96]. Recently ghrelin
levels have been found decreased in liver failure patients
[101], a clinical condition with altered nutrition and glucose
homeostasis. When Gauna et al. studied the eﬀects of AG
and UAG on primary hepatocytes; they confirmed that
ghrelin in vitro induces a rapid increase of glucose output
by primary hepatocytes, which suggests that AG modulates
glucose homeostasis at least by acting directly on the liver.
It was found that UAG itself exerts an inhibitory eﬀect on
glucose output and; as was seen in normal subjects in vivo,
it is able to counteract the inductive eﬀect of AG on glucose
release [96]. The results obtained by diﬀerent authors appear
to indicate that the administration of UAG in humans might
improve insulin sensitivity and secretion in subjects with
relative or absolute GH deficiency and in the presence of GH.
These eﬀects of UAG in the regulation of glucose
metabolism might be of therapeutic interest for those
pathological conditions characterized by insulin resistance
and impaired insulin release.
3. Effects of Endogenous Ghrelin on
Glucose and Insulin Levels
3.1. Studies In Vivo with GHSR Antagonists. In order to study
the eﬀects of endogenous ghrelin on glucose and insulin
metabolism, many investigators used GHSR antagonists like
modified GHRP-6 or YIL-781. In normal mice blockade of
endogenous ghrelin by intraperitoneal injection of modified
GHRP-6 markedly lowered fasting glucose concentrations
in a few hours. Similarly during the intraperitoneal glu-
cose tolerance test (IP-GTT), plasma glucose elevation was
attenuated and insulin response was enhanced, showing a
physiological role for endogenous ghrelin in the regulation
of insulin release and blood glucose [58]. On the other hand
YIL-781 did not aﬀect fasting blood glucose levels. But, upon
IP-GTT, the compound as well as modified GHRP-6 caused
a decrease in the glucose excursion relative to the vehicle-
treated animals. During an insulin tolerance test (ITT), YIL-
781 did not alter the eﬀect of insulin on blood glucose
levels. This result, in combination with the eﬀect of the
compound on insulin secretion, demonstrates that, at least
acutely, the GHSR1a antagonist YIL-781 improves glucose
tolerance by promoting insulin release rather than enhancing
insulin sensitivity. To evaluate whether GHSR1a antagonists
could improve glucose tolerance in a disease model, YIL-
781 was tested in the insulin-resistant diet-induced obesity
(DIO) rat. In this model an oral dose of YIL-781 causes a
reduction in glucose excursion. [92]. The data obtained by
Esler et al. provide evidence that GHSR1a antagonists had no
apparent eﬀect on insulin sensitivity but improved glucose
tolerance by stimulating insulin secretion. When ob/ob obese
mice, which are a known genetic model of obesity and
diabetes with insulin resistance, were peripherally admin-
istered with modified GHRP-6 during several days, plasma
glucose levels diminished. This reduction in glucose levels
was accompanied by a moderate decrease in serum insulin
levels, suggesting that GHSR antagonists ameliorated insulin
resistance in the long term [75].
The data obtained with GHSR1a antagonists (summa-
rized in Table 4) suggest that these drugs could improve glu-
cose tolerance and ameliorate insulin resistance in the long
term and hence may be promising targets for pharmacologi-
cal intervention in the treatment of type 2 diabetes.
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Table 4: Eﬀects of GHSR antagonists on glucose and insulin levels.
Species
Treatment
Administration
Dose Feeding
Measurement
blood samples
Plasma glucose
levels
Plasma insulin
levels
Reference
Mice ob/ob
1 IP GHSR
antagonist
injection/12 hours
versus 1 IP placebo
injection
200 nmol
GHRP-
6/mouse
Ad libitum
SCD
Endpoint 6-day Diminished Diminished [75]
Mice ddY
1 IP GHSR
antagonist injection
versus 1 IP placebo
injection
10 μmol
GHRP-6/kg
Fasting
overnight
Time course
2 hours
Diminished Enhanced
1 IP GHSR
antagonist injection
versus 1 IP placebo
injection
1 μmol
SPA/kg
Fasting
overnight
Time course
2 hours
Diminished Enhanced [58]
1 IP GHSR
antagonist + ghrelin
injection versus 1 IP
ghrelin injection
1 μmol
GHRP-6/kg
+10 nmol
ghrelin/kg
Fasting
overnight
End point
0.5 hours
Diminished
Normal rats
1 IP GHSR
antagonist injection
versus 1 IP placebo
injection
10 μmol
GHRP-6/kg
Fasting
overnight
End point
0.5 hours
Enhanced
[91]
Gastrectomized
rats
1 IP GHSR
antagonist injection
versus 1 IP placebo
injection
10 μmol
GHRP-6/kg
Fasting
overnight
End point
0.5 hours
Enhanced
Normal rats
Oral GHSR
antagonist +
IP-GTT versus
IP-GTT
10 mg
YIL-781/kg
+2 g
glucose/kg
Fasting
overnight
Time course
6 hours
Diminished Enhanced
[92]
Oral GHSR
antagonist versus
placebo
30 mg
YIL-781/kg
Fasting
overnight
Time course
6 hours
Diminished
DIO rats
Oral GHSR
antagonist +IP-GTT
versus placebo +
IP-GTT
3 mg
YIL-781/kg
+2 g
glucose/kg
Fasting
overnight
Time course
6.5 hours
Diminished
3.2. Glucose and Insulin Levels in GHSR-, Ghrelin-, and
Double-Knockout Animals. The knockout (KO) animals rep-
resent a good opportunity to study endogenous ghrelin func-
tions. Plasma ghrelin concentration is inversely correlated
with body weight and body fat [102]. Moreover, considering
that one of the main characteristics of exogenous ghrelin is
to increase food intake, body weight, and % body fat [10, 87]
it was expectable that the null animal for ghrelin and/or
GHSR had marked diﬀerences in the ingestion and/or body
composition; however the results obtained did not show
that. It seems that the type of diet, its duration, age, and
nutritional status of the animals are key factors to understand
the function of the hormone in the energetic metabolism as
well as its eﬀect in the homeostasis of glucose and insulin.
The results obtained in rats in relation to the metabolism
of glucose and insulin in knockout animals are shown in
Table 5.
3.2.1. GHSR Knockout. Some investigators reported that
GHSR knockout animals, in comparison with wild-type
controls, had only a modest decrease in body weight when
maintained on standard chow and similar levels of insulin
in both fed and fasted states [106]. However GHSR null
mice to 50% caloric restriction (CR) or fasting conditions on
standard diet had lower blood glucose and insulin levels than
standard diet fed wild-type (WT) mice suggesting enhanced
insulin sensitivity [34]. These results were supported by other
authors. Zigman et al. also observed that GHSR-null male
mice showed lower blood glucose levels when maintained
on a standard chow diet (SCD), and corresponding insulin
levels were lower, although not always reached statistical
significance [104].
It was observed that GHSR null mice had mean body
weight and body composition comparable to those of
their same-sex wildtype littermates when measured 1 week
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Table 5: Glucose and insulin levels in GHSR-, ghrelin-, and double-knockout animals.
Null mice Treatment Dose
Food before/during
experiment
Measurement
blood samples
Plasma glucose
levels
Plasma
insulin levels
Reference
Ghrelin KO versus wildtype SCD 4–20 weeks old Endpoint Not change Not change [35]
Ghrelin KO versus wildtype
SCD 4–10 weeks of
age
Endpoint Not change Not change [103]
Ghrelin
IP-GTT, KO versus
wildtype
2 g glucose/kg SCD, fasted
Time course-2
hours
Diminished Enhanced
[91]
KO versus wildtype SCD, fed Endpoint Endpoint Not change
KO HDF versus KO
SCD
HFD 8–12 weeks
old
Endpoint Not change Enhanced
IP-GTT, KO HFD
versus KO SCD
2 g glucose/kg
HFD 8–12 weeks
old
Time course-2
hours
Not change Enhanced
Ghrelin
IP-GTT, KO versus
wildtype
2.5 g glucose/kg SCD 8-week old
Time course-2
hours
Diminished Enhanced [36]
Ghrelin KO versus wildtype SCD, 6 hours fast Endpoint Not change Not change [37]
AG versus saline
2.5 g glucose/kg +
1 IP injection of
150 nmol AG/kg
SCD 8-week old,
18 h fast
Time course-2
hours
Enhanced Diminished
[36]
ITT, KO versus
wildtype
0.75 U/kg
SCD 8-week old, 8h
fast
Time course-2.5
hours
Diminished
Ghrelin
Hyperinsulinemic-
euglycemic clamp, KO
versus wildtype
SCD 8-week old
GIR enhanced
during clamp
KO versus wildtype SCD 12-week old Endpoint Not change Not change
KO.ob/ob versus
wildtype.ob/ob
SCD 12-week old Endpoint Diminished Enhanced
KO.ob/ob versus
wildtype.ob/ob
SCD 12-week old,
24 hours fast
Endpoint Diminished Not change
Ghrelin
IP-GTT, KO versus
wildtype
2 g glucose/kg SCD, 6 hours fast
Time course-2
hours
Not change Not change
[37]
ITT, KO versus
wildtype
1 U/kg SCD, 6 hours fast
Time course-2
hours
Not change Not change
Ghrelin
O-GTT, KO DIO
versus wildtype DIO
1 g glucose/kg
HFD 8–23 weeks
old, 16 hours fast
Time course-2
hours
Not change Diminished [33]
Ghrelin KO versus wildtype
10-week SCD + 40
days on 50% caloric
restriction with
SCD
Time course
every 2 days
2–16 day
diminished
[34]
KO DIO versus
wildtype DIO
HFD 8–23 weeks
old
Endpoint diminished Diminished
IPGTT, KO DIO
versus wildtype DIO
1 g glucose/kg
HFD 8–23 weeks
old, 16 hours fasted
Time course-2
hours
Not change Diminished
[33]
Ghrelin Hyperinsulinemic-
euglycemic clamp, KO
DIO versus wildtype
DIO
10 mU insulin/kg
+ constant
infused insulin
5 mU/kg/min +
infused 20%
glucose
HFD 8–23 weeks
old, 16 hours fast
Time course-1.5
hours
GIR enhanced
Hyperglycemic clamp
KO DIO versus
wildtype DIO
20% glucose at
rates that
stabilized blood
glucose at
300 mg/dl
HFD 8–23 weeks
old, 16 hours fasted
Time course-1.5
hours
Diminished
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Table 5: Continued.
Null mice Treatment Dose
Food
before/during
experiment
Measurement
blood samples
Plasma glucose
levels
Plasma
insulin levels
Reference
KO versus wildtype 24-week SCD Endpoint Not change Not change
KO versus wildtype
24-week
SCD/18 h-fasting
Endpoint Diminished Diminished
GHSR KO versus wildtype
10-week SCD + 40
days on 50%
caloric restriction
with SCD
Time course
every two days
2–28 day
diminished
[34]
KO versus wildtype
14-week SCD
+10-week HF +
18 h-fasting
Endpoint Not change Not change
KO versus wildtype
14-week SCD
+10-week HF
Endpoint Not change Not change
IP-GTT KO versus
wildtype
2 g glucose/kg
SCD, 6
hours-fasting
Time course 2
hours
Not change Not change
[37]GHSR
ITT KO versus
wildtype
1 U/kg
SCD, 6
hours-fasting
Time course 2
hours
Not change Not change
KO versus wildtype
SCD, 6
hours-fasting
Endpoint Not change Not change
GHSR KO versus wildtype
SCD 4–19 weeks
old
Endpoint Diminished Diminished [104]
GHSR KO versus wildtype SCD 8-week old Endpoint Diminished Diminished [105]
Ghrelin +
GHSR
IP-GTT dKO versus
wildtype
2 g glucose/kg
SCD, 6
hours-fasting
Time course-2
hours
Not change Not change
[37]dKO versus wildtype
SCD, 6
hours-fasting
Endpoint Not change Not change
ITT dKO versus
wildtype
1 U/kg
SCD, 6
hours-fasting
Time course-2
hours
Not change Not change
after weaning or exposure to standard chow. However,
several weeks of exposure to HFD after weaning resulted in
significantly less accumulation of both body weight and body
fat content in GHSR null mice, as compared with littermate
controls, and these animals presented resistance to diet-
induced obesity [33, 104]. Interestingly, these diﬀerences are
masked in HFD fed mice only in their adult stage; in this
situation the deletion of GHSR does not prevent DIO or
weight gain after weight loss [34].
Once more, in GHSR null mice fed with HFD, sev-
eral measures of greater insulin sensitivity were observed,
including lower fasted blood glucose and plasma insulin,
lower insulin levels during glucose tolerance tests, and
improved performance in hyperinsulinemic-euglycemic and
hyperglycemic clamp studies [33].
On the other hand, the results obtained in RQ for GHSR
null mice are discrepant. The knockout created by Nakano
et al. presented decreased RQ during long-term HFD study
that represents a shift in metabolic fuel preference toward
the utilization of fat as an energy substrate [104]. On the
contrary, Longo’s animals have higher RQ, indicating a pref-
erence for carbohydrate as fuel regardless of gender or diet.
These data could suggest that ghrelin’s eﬀects on metabolic
fuel preference are transient and may not have a significant
eﬀect throughout the lifespan. Perhaps adult GHSR null
mice are subject to metabolic adaptations especially in regard
to energy intake and expenditure. However the range of
RQ values was wider in knockout mice, indicating greater
metabolic flexibility in these animals [33].
3.2.2. Ghrelin Knockout. When ghrelin KO animals and WT
controls were exposed to prolonged and earlier HFD (after
weaning), ghrelin KO mice showed mean body weight and
mean body fat percentage that were lower than those of
similarly treated wild-type controls [107]. This diet produced
glucose intolerance and insulin resistance in wild type
mice [91, 107]. By contrast, ghrelin knockout mice fed
with HFD showed close to normal glucose responses and
markedly enhanced insulin responses to IP-GTTs compared
with control ghrelin knockout mice fed with SCD [91]. As
a possible underlying mechanism Dezaki et al. suggested
that lack of ghrelin and its insulinostatic activity may raise
the maximal capacity of glucose-induced insulin release and
enable islets to secrete more insulin to meet an increased
demand associated with HFD–induced obesity, thereby
achieving normoglycemia [91]. Moreover Ghr KO mice on
the HFD presented lower levels of glucose and insulin as well
as lipids compared with wild-type on this diet; hence ghrelin
as well as GHSR null mice exposed to HFD after weaning
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exhibit greater glucose tolerance. The results of GTTs and
ITTs were similar to those previously observed for the same
authors with pharmacological blockade of ghrelin action
[58], reinforcing the concept that endogenous ghrelin serves
as a regulator of insulin release and of glycemia. However,
when ghrelin null mice and wild type mice were subjected to
acute exposure to HFD late in life, slight diﬀerences in body
composition between ghrelin KO animals and wild-type
controls were reported, and no change in glucose and insulin
levels [103]. Comparable results were obtained in animals
fed with standard chow, where insulin and glucose levels did
not display changes [35]. Moreover these animals did not
display diﬀerences in cumulative food intake on standard
chow or body weight change and food intake in response to
reexposure to food following a fast [35]. However, Sun et al.
realized several studies where they observed, that compared
to WT, ghrelin KO mice exhibited significantly lower glucose
levels after IP-GTT and correspondingly higher levels of
insulin. In addition, the initial insulin response at 15 minutes
was significantly higher in the ghrelin KO compared to
WT mice [36]. When ghrelin KO mice were subjected to
50% caloric restriction, they had lower blood glucose levels
than their WT littermates suggesting that ghrelin would be
involved in providing a counterregulatory glucose response
during negative energy balance [34].
In another line of ghrelin knockout mice, glucose levels
were monitored in lean mice (wild-type and ghrelin KO)
and obese mice (wild type ob/ob and ghrelin KO ob/ob)
at diﬀerent ages [36]. The lean mice were euglycemic; as
expected, glucose and insulin levels were elevated both in
ob/ob and ghrelin KO ob/ob mice. However blood glucose
was elevated at age 4 weeks in ob/ob mice and at 6
weeks in ghrelin KO ob/ob mice, and although obesity was
as severe as in ob/ob mice, ghrelin KO ob/ob exhibited
lower glucose levels and their blood glucose normalized
upon fasting. Hence, ablation of ghrelin markedly improved
glucose homeostasis in ob/ob mice [36]. The improvement
in glucose homeostasis in ghrelin KO ob/ob mice was
accompanied by increased serum insulin levels. Remarkably,
compared to ob/ob mice, ghrelin KO ob/ob mice displayed
reduced blood glucose concentrations after IP-GTT, which
was accompanied by increased insulin secretion [36]. When
ghrelin KO mice, maintained from weaning on regular
chow, were subjected to IP-GTT, ghrelin treatment produced
higher blood glucose and markedly lowers insulin levels,
showing that ghrelin acutely suppresses insulin release,
suggesting that the improved glucose tolerance which was
observed in ghrelin KO ob/ob mice fed with HFD during IP-
GTT could be a consequence of ghrelin-ablation. Moreover,
ghrelin ablated mice presented greater reductions in glucose
levels 30 minutes following ITT suggesting increased insulin
sensitivity. When the authors subjected WT and ghrelin
KO mice to euglycemic hyperinsulinemic clamp studies,
basal hepatic glucose production rate was the same in
both genotypes. But during the low-dose insulin clamp,
suppression of glucose production was higher in ghrelin
KO mice, proposing once more that the liver of ghrelin
KO mice was more sensitive to insulin. Furthermore, an
increase in glucose infusion rate (GIR) and an increase
in GDR were detected, indicating that besides increasing
glucose-induced insulin secretion, ghrelin ablation increased
peripheral insulin sensitivity and improves glucose tolerance
[36].
Wortley et al. found a trend toward decreased weight
and leaner body composition in male ghrelin knockout mice
after 6 weeks on the HFD, which could be explained by a
decrease in RQ observed only in these animals; therefore the
constitutive absence of ghrelin causes a distinct shift toward
lipid metabolism during consumption of an HFD [103].
3.2.3. Ghrelin/Ghrelin Receptor Double Knockout (dKO) Mice.
Pfluger and colleagues created ghrelin/ghrelin receptor dou-
ble knockout mice. Plasma glucose and plasma insulin levels
did not diﬀer between aged WT and dKO mice after an
overnight fast. An IP-GTT overall failed to reveal significant
diﬀerences in glucose tolerance between genotypes. Mice
deficient in either ghrelin, GHSR, or both showed lower
glucose peak levels at a single time point (15 minutes
after the injection) suggesting a slightly faster release of
insulin. Mice were subjected to an ITT; in ghrelin KO mice
glucose levels were similar to WT mice. In dKO and GHSR
KO mice, glucose levels, however, dropped more rapidly.
In general, glucose levels of dKO and GHSR mice tended
to remain lower throughout the 120 minutes of the ITT,
compared with WT mice. However, although integrated
glucose levels in both GHSR KO and dKO mice tended to
be lower compared with WT control mice, the deficiency
of ghrelin, its receptor, or both did not seem to have a
major impact on overall insulin sensitivity or the overall
regulation of glucose homeostasis. They observed substantial
but mostly insignificant trends in glucose tolerance and
insulin sensitivity. Importantly, all these data were obtained
from mice maintained on normal standard chow diet [37].
Pfluger et al. speculated that their mouse mutants still
may exhibit some level of ghrelin signaling, although by
definition they genetically deleted ghrelin [9], its putative
ghrelin associated peptide [108], ghrelin splice variants
[109], and the constitutively active ghrelin receptor GHSR
[110]. For this reason the authors suggested that the existence
of both additional ligand and additional receptor, coded for
by genes other than the ghrelin and the GHSR gene, could
explain why the dKO mouse shows a phenotype that still has
to be categorized as very mild.
In summary, the results obtained with knockout animals
seem to indicate that ghrelin is not a critical orexigenic
factor. Nevertheless, the ghrelin/GHSR pathway plays a role
in glucose homeostasis by regulating insulin sensitivity and
glucose sensing. If it was confirmed that ghrelin ablation
restores the first-phase of insulin secretion, as observed in
ghrelin knockout ob/ob mice, [36] this could have clinical
relevance, because in humans the loss of first-phase insulin
secretion is predictive for the development of type 2 diabetes
[111]; therefore, in subjects at risk for type 2 diabetes,
treatment with a ghrelin antagonist may prove beneficial.
Kelley and colleagues proposed a central pathophysiological
construct to describe the altered metabolism associated with
insulin-resistant and glucose-intolerant states: the concept of
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Table 6: Relation between overexpression of ghrelin in diﬀerent tissues or cellular types and glucose-insulin levels.
Transgenic animals
Ghrelin
levelstransgenic
versus wildtype
Treatment
Food
before/during
experiment
Treatment
duration
Plasma glucose
levels transgenic
versus wildtype
Plasma insulin
levels transgenic
versus wildtype
Reference
Ghrelin is overexpressed
inadipose tissue
AG: not change
UAG: enhanced
Nothing Ad libitum Endpoint Enhanced
[26]IP-GTT 16-h fast 2.5 hours Diminished
IP-ITT 16-h fast 2.5 hours Diminished
Ghrelin is overexpressed
in stomach and
hypothalamus
AG: enhanced
UAG: enhanced
IP-GTT 18-h fast 2.5 hours Enhanced Diminished
[113]
IP-ITT 4-h fast 2.5 hours Not change Not change
Ghrelin is overexpressed
in pancreas
AG: not change
UAG: enhanced
Nothing Overnight fast Endpoint Not change Not change
[39]IP-GTT Overnight fast 2 hours Not change Diminished
IP-GTT Overnight fast 2 hours Not change Diminished
ITT 4-h fast 3 hours Not change Not change
Ghrelin is overexpressed
in hypothalamus, cortex
and liver
AG: enhanced
UAG: enhanced
IP-GTT 20-h fast 2 hours Enhanced Not change
[114]Ghrelin is overexpressed
in hypothalamus, cortex
and liver
AG: not change
UAG: enhanced
IP-GTT 20-h fast 2 hours Not change Not change
Ghrelin is overexpressed
in wide variety of tissues
AG: not change
UAG: enhanced
Nothing Ad libitum Endpoint Not change Not change [27]
“metabolic inflexibility” [112]. Metabolically normal people
can adapt to the discontinuities in fuel availability and
utilization present in daily life, whereas diabetic people
cannot. Metabolic inflexibility means that insulin-resistant
individuals are unable to eﬃciently increase carbohydrate
utilization, even when carbohydrates are plentiful. This is a
rewording of the essence of impaired glucose tolerance (and
insulin resistance). The results obtained in RQ of GHSR KO
mice seem to indicate greater metabolic flexibility and hence
improve glucose tolerance. When null mice were fed with
either SCD or HFD, their body weights were not diﬀerent
from that of their WT littermates on the same diet. However
ghrelin and GHSR null mice were resistant to DIO when
were fed with HFD immediately after weaning. But ablation
of the ghrelin/GHSR signal does not prevent DIO raised on
SCD and then fed with HFD as adults. Considering these
data it would be possible to conclude that the loss of ghrelin
signalling protects against several fatty diet-induced features
of metabolic syndrome and improves insulin sensitivity. But
all these results should be taken with caution, considering
that the age of exposition and the type of diet seem to be key
factors to observe the eﬀect of ghrelin on glucose and insulin
metabolism.
3.3. Glucose and Insulin Levels in GHSR and Ghrelin Trans-
genic Animals. There are some studies realized with ghrelin
transgenic mouse with overexpression of ghrelin in diﬀerent
tissues or cellular types (Table 6). Many of them presented
plasma UAG levels higher than those of their nontransgenic
littermates whereas that plasma acylated ghrelin levels did
not change [27, 38, 39]. Hence these models can serve to
study the role of desacyl as well as acylated ghrelin in the
regulation of glucose metabolism and insulin release.
Iwakura and colleagues developed and analyzed rat
insulin II promoter-ghrelin transgenic mice (RIP-G Tg) in
which pancreatic ghrelin concentration was higher than
that of nontransgenic littermates; moreover in control mice
ghrelin was not detected in β-cells by immunohistochem-
istry. Ghrelin transgene driven by RIP was considered to
be expressed in β-cells, although higher expression levels
of ghrelin mRNA were also found in the brain of RIP-
G Tg compared with that of nontransgenic littermates.
When these animals were subjected to IP-GTT, plasma
insulin levels were significantly lower in Tg mice than
those in nontransgenic littermates, although there was no
significant diﬀerence in plasma insulin levels between RIP-
G Tg and nontransgenic littermates on the fasting state
[39]. The glucose-stimulated insulin secretion of RIP-G Tg
was decreased without changes in glucose levels, but there
were no abnormalities with the arginine-induced insulin
secretion, pancreatic histology, pancreatic insulin mRNA
levels, and insulin content in the RIP-G Tg. When the
authors did several tests from isolated islets of RIP-G Tg,
they found that insulin secretion as well as immunoreactivity
of glucose transporter in the pancreatic β cell, in RIP-G Tg
β cells, was indistinguishable from that of nontransgenic
littermates, indicating that insulin secretion was not aﬀected
by overexpression of ghrelin transgene in vitro, although it
was aﬀected in vivo [39]. When these animals were subjected
to ITT, they showed a tendency to lower blood glucose
levels. Considering the results, the authors suggested that the
suppression of insulin secretion of RIP-G Tg is likely due
to the eﬀect of desacyl ghrelin on insulin sensitivity [39].
Nevertheless these results do not agree with others studies.
Reed et al. created mice with ghrelin overexpressed in
neurons using the neuron-specific enolase (NSE) promoter
14 International Journal of Peptides
sequences and mouse ghrelin cDNA (NSE-ghrelin). Ghre-
lin expression in NSE-ghrelin brain tissues was increased
compared with wild-type mice; it was also increased to a
much smaller extent in liver of these mice, but in stomach
or duodenum did not diﬀer from wild-type mice. They
worked with two lines of NSE-ghrelin mice: one line with
increased circulating AG and UAG (L43) and one line with
only UAG (L73). In both lines young NSE-ghrelin mice
had normal glucose tolerance; however, L43 NSE-ghrelin
mice, but not L73 mice, developed glucose intolerance at
32 week of age. Despite the impaired glucose tolerance
in L43 mice, insulin levels did not diﬀer from those of
wild-type mice [114]. However, unlike the studies from
Iwakura et al. plasma insulin levels did not change after IP-
GTT in those animals with high levels of UAG (L73). The
diﬀerences between both studies can be the consequence
of several factors like age or others. In another line of
transgenic mice, Zhang et al. created animals in which the
ghrelin gene is overexpressed in adipose tissue via the fatty
acid-binding protein-4 (FABP4) promoter. Transgenic mice
overexpressing the ghrelin gene in adipose tissue demon-
strated significant increases in plasma concentrations of
UAG, whereas ghrelin remained unchanged. Overexpression
of ghrelin from the FABP4 promoter reduced the weight
of white adipose tissues and resistance to HFD-induced
obesity [26]. Alterations in glucose tolerance and insulin
sensitivity tests were detected in FABP4-ghrelin transgenic
mice. When these animals were subjected to IP-GTT, glucose
levels were significantly lower than in controls; however
FABP4-ghrelin transgenic mice had a greater hypoglycemic
response to insulin administration than control animals.
It seems that UAG improves glucose tolerance and insulin
sensitivity, providing more evidences that UAGs play a role
in the regulation of glucose metabolism. These data are
strengthened by the observation that plasma insulin levels are
elevated in transgenic mice [26].
Recently, Bewick et al. generated a mouse model with
increased ghrelin expression and production in stomach
and brain. Ghrelin transgenic mice exhibited increased
circulating AG and total ghrelin which was associated
with hyperphagia and increased energy expenditure. These
animals were subjected to IP-GTT and ITT; the animals were
glucose intolerant due to an inhibition of glucose-stimulated
insulin release but without change in insulin sensitivity
[113].
4. Mechanism of Action
In order to understand how ghrelin can modify glucose
and insulin homeostasis, it is important to study the
mechanism of action exerted by ghrelin in tissues implied in
carbohydrate metabolism.
4.1. Liver. De novo synthesis of glucose in the liver from pre-
cursors such as lactate, gluconeogenic amino acids, and glyc-
erol is a central mechanism to provide the organism with glu-
cose in times of starvation [115], a natural situation in which
ghrelin levels are increased [10, 30]. On the other hand,
when glucose is directly available from external resources,
gluconeogenesis is dispensable and consequently needs to
be shut oﬀ. Integration of these events is complex and
occurs through various hormonal and nutritional factors.
The principal parameters aﬀecting hepatic glucose output
are the concentrations of the available glucogenic substrates
and the activity of a few regulatory enzymes. The activity
of the key gluconeogenic enzymes phosphoenolpyruvate
carboxykinase (PEPCK) and G6Pase is regulated by tran-
scriptional and nontranscriptional mechanisms, whereas the
third key enzyme fructose-1,6-bisphosphatase (FBPase) is
also regulated through competitive inhibition by fructose
2,6-bisphosphate. Insulin is the most important hormone
that inhibits gluconeogenesis, through the activation of the
insulin receptor (IR). It acts predominantly by suppressing
the expression of the genes for the key gluconeogenic
enzymes PEPCK and G6Pase [116]. In the H4-II-E-cells (rat
hepatoma cell line) and HepG2 cells (human hepatocellular
carcinoma cell line) ghrelin was shown to stimulate insulin
receptor substrate 1o(IRS1) and its downstream molecules,
including growth factor receptor-bound protein 2 (Grb2)
and mitogen-activated protein kinase (MAPK). Whereas
on the other hand, it diminished phospho protein kinase
B (pAKT) and phospho-glycogen synthase kinase (pGSK)
levels in both cell lines and upregulated gluconeogenesis
in H4-II-E-cells by attenuating the eﬀect of insulin on the
expression on PEPCK [73].
AKT is a key protein kinase downstream of the insulin
receptor [117] and its activation plays a key role in suppress-
ing hepatic gluconeogenesis [118, 119], since GSK-3, which
phosphorylate glycogen synthetase (GS) is inhibiting, is
phosphorylated by AKT, and this phosphorilation inactivates
GSK-3 kinase activity, suppressing hepatic gluconeogenesis
resulting in enhanced glycogen deposition [118].
Forkhead box O1 (FOXO1) and peroxisome proliferator
activated receptor-γ-coactivator (PGC)-1α are two tran-
scriptional components that are targets of insulin signalling
and that can activate the process of gluconeogenesis in liver.
FOXO1 has been shown to bind directly to the promoters
of gluconeogenic genes and activate the process of glucose
production [120–122]. It is directly phosphorylated by AKT.
This phosphorylation results in exclusion of FOXO1 from
the nucleus. A second transcriptional component controlled
by insulin and having a role in gluconeogenesis is the
coactivator PGC-1α. It is induced in the liver during fasting
and is elevated in several models of diabetes or deficiency
in insulin signalling. Notably, expression of PGC-1α at
physiological levels turns on the entire program of gluco-
neogenesis [123]. PGC-1α hepatic transcription has been
reported to be downregulated by AKT activation through
forkhead transcription factor FOXO1 phosphorylation and
nuclear exclusion [124].
Barazzoni et al. observed that in rats sustained ghrelin
administration reduced hepatic phospho/total-AKT (P/T-
AKT) and P/T-GSK [86]. These changes in AKT-GSK sig-
nalling were associated with enhanced PGC-1α expression.
Reduced liver AKT signaling could potentially contribute to
concomitant blood glucose increments, preserving hepatic
glucose production in calorie-restricted status [86].
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The routes that have been modified after treatments with
ghrelin in liver and which could modify plasma glucose levels
are represented in Figure 1.
4.2. Pancreas. Insulin secretion is accurately linked to blood
glucose levels in the physiological range. The role of the β-
cells is to sense an increase in the concentration of nutrients
in the blood and to synthesize, package, and release insulin
to control blood glucose homeostasis. Various agents as
amino acids (particularly arginine and leucine) and fatty
acids can increase the secretion of insulin, but only in the
presence of facilitating concentrations of glucose (above
3 mM), whilst nonmetabolizable analogues of glucose such
as galactose or fructose are inactive as secretagogues [125].
The above fuel secretagogues are initiators of secretion,
but there are also other agents including neurotransmitters,
glucagon-like peptide (GLP-1), gastric inhibitory peptide
(GIP), and pituitary adenylate cyclase-activating polypeptide
(PACAP) that act as “potentiators”, enhancing secretion only
at permissive concentrations of fuel secretagogues. These
molecules usually act via G-protein coupled receptors and
the generation of classical second messengers such as cAMP
and Ca2+ [126]. The first studies about stimulus-secretion
coupling in β-cells early concluded that glucose must be
metabolized by β-cells to induce insulin secretion, Ca2+ has
an essential role in insulin secretion, and pancreatic β-cells
are electrically excitable [125].
Islet β-cells are equipped with high-capacity glucose
transporters located at the plasma membrane that are
known as glucose transporters-2 (GLUT-2) [127]. GLUT-
2 is required for eﬃcient glucose-stimulated insulin secre-
tion, as demonstrated by studies in transgenic mice [128,
129]. β-cells contain a high Km glucokinase (glucose-
phosphorylating hexokinase, GK), which displays strongly
cooperative kinetics and has thus been termed the β-
cell “glucose sensor.” The reduction in β-cell GK levels
was associated with reduced capacity to secrete insulin in
response to glucose [130]. Glucose stimulation of insulin
secretion involves two pathways: the triggering of ATP-
sensitive K+channel- (KATP-) dependent pathway, and the
amplifying of KATP channels-independent pathway. The
rise in blood glucose induces an increase in β-cell glucose
metabolism, resulting in increased production of ATP from
several sources: glycolysis, mitochondrial glucose oxidation,
and active shuttling of reducing equivalents from the cytosol
to the mitochondrial electron transport chain. The resul-
tant increase in ATP/ADP ratio inhibits KATP channels,
depolarizing the plasma membrane, leading to opening of
the voltage-dependent calcium channels (VDCCs), which
allows calcium influx. The resultant intracellular calcium
concentration ([Ca2+]i) rise triggers exocytosis of the
insulin-containing granules (reviewed in [131]). However,
an expanding bulk of data also makes it apparent that this
KATP-channel dependent mechanism of glucose-stimulated
insulin secretion does not fully describe the islet glucose
response, and signals other than changes in ATP: ADP ratio
have been increasingly implicated as important regulators
of insulin secretion in recent years. The voltage-dependent
K+ channels (Kv) [132] are thought to repolarize glucose-
stimulated action potentials and inhibit Ca2+ entry through
voltage-gated Ca2+ channels; therefore, Kv channels serve
as negative regulators of insulin secretion, and Kv chan-
nel antagonists are insulinotropic in a glucosedependent
manner. Kv channels are comprised of the pore-forming α
subunits (Kv2.1 is thought to be the predominant isoform
in islet β-cells) and regulatory β-subunits, analogous to the
pore-forming and regulatory subunits of the KATP channel
complex. Kv channel β–subunits are proposed to act as
intracellular redox sensors, and an increase in cytosolic
NADPH : NADP ratio in patch-clamped-cells was shown to
be associated with an increased rate of inactivation of the
Kv channel [133]. Inhibition of Kv channels by NADPH,
derived from pyruvate cycling, could serve as a logical
complementary mechanism to ATP regulation of KATP
channel activity, since suppression of Kv channels would
slow membrane repolarization, allowing the eﬀects of KATP
channel inhibition to be sustained through a second phase
of insulin secretion (Figure 2). But this model is not fully
established (reviewed in [134]).
In rat isolated islets, several works showed that endoge-
nous and exogenous ghrelin suppressed glucose-induced
insulin release [58, 91, 92, 135]. Dezaki et al. presented ghre-
lin signalling in β-cells. They observed that in rats ghrelin of
both endogenous and exogenous origin resulted in pertussis
toxin- (PTX-) sensitive decrease in plasma insulin concentra-
tions, contrasting with PTX-insensitive increase in GH levels
by ghrelin [58, 136]. PTX catalyzes the ADP-ribosylation
of the α subunits of the heterotrimeric G proteins Gi, Go,
and Gt. This prevents the G proteins from interacting with
G protein-coupled receptors on the cell membrane, thus
interfering with intracellular communication. Since the Gα
subunits remain in their GDP-bound, inactive state, they
are unable to inhibit adenylyl cyclase, thus keeping levels
of adenylyl cyclase and cAMP elevated [137]. In intact
cells, PTX inhibited a number of insulin-stimulated cellular
events, such as glucose transport and its metabolism. The
function of endogenous ghrelin was assessed by the eﬀects of
GHSR antagonist in vivo and in rats treated with ghrelin and
PTX. In addition, studies with isolated islets from ghrelin-
KO mice observed that modified GHRP-6 increased plasma
insulin concentrations after IP administration, indicating
suppression of insulin levels by endogenous ghrelin. The
insulinostatic eﬀect of ghrelin was unaltered by pretreatment
with phospholipase C (PLC) inhibitor. However the eﬀects
of endogenous and exogenous ghrelin on insulin levels were
not observed in PTX-treated rats. In islets isolated from
ghrelin-KO mice, glucose-induced insulin release was greater
than those from wild-type mice. This enhancement was
blunted by pretreatment with PTX. They observed that
ghrelin increased Kv currents and that tetraethylammonium
(TEA), a Kv channel blocker, eliminated the ability of ghrelin
to suppress insulin release. Furthermore, ghrelin treatment-
inhibited glucose induced [Ca2+]i increases in β-cells. All
the eﬀects of endogenous and exogenous ghrelin on Kv
and [Ca2+]i as well as insulin release were blunted in the
presence of PTX. This finding suggests that glucose-induced
insulin release in islets is markedly decreased by endogenous
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Figure 1: Regulation of hepatic gluconeogenesis and glycogen synthesis by ghrelin. Insulin activates the insulin receptor tyrosine kinase
(IR), which phosphorylates and recruits diﬀerent substrate adaptors. AKT is a key protein kinase downstream of the insulin receptor
and its activation plays a key role in suppressing hepatic gluconeogenesis, since GSK-3, which phosphorylate glycogen synthetase (GS) is
inhibiting, is phosphorylated by AKT suppressing hepatic gluconeogenesis, resulting in enhanced glycogen deposition. Sustained ghrelin
administration in rats reduced hepatic AKT-GSK activation and enhanced PGC-1a expression, suggesting upregulation of gluconeogenesis
and downregulation of glyconeogenesis.
ghrelin. Endogenous ghrelin in islets restrict glucose-induced
insulin release via the following mechanism: ghrelin directly
acts on the β-cell GH secretagogue receptor and via PTX–
sensitive mechanisms attenuates glucose-induced [Ca2+]i
signalling, partly through enhancement of TEA-sensitive
delayed outward K+currents [58, 136]. When the islet β-cells
were treated with the antisense oligonucleotide specific for
Gαi2-subunit of G proteins, the eﬀects of ghrelin on [Ca2+]i
and insulin release were abolished (Figure 2). These findings
demonstrate that ghrelin suppresses glucose-induced insulin
release via Gαi2- and Kv channel–mediated attenuation of
Ca2+ signalling in β-cells [136].
All these data reveal that endogenous ghrelin in islets
acts on β-cells to restrict glucose-induced insulin release,
at least partly via attenuation of Ca2+ signaling, and that
this insulinostatic action may be implicated in the upward
control of blood glucose. These unique signaling mech-
anisms and molecules mediating the insulinostatic action
of ghrelin on β-cells provide potential therapeutic targets
for the prevention and treatment of type 2 diabetes and
hyperinsulinemia [58, 136].
4.3. Adipocytes. The insulin stimulation of glucose uptake
in adipose and muscle tissue occurs through a complex
and as yet incompletely defined signalling pathway acting
through the insulin receptor tyrosine kinase. The primary
eﬀect is to promote the movement of the GLUT-4 protein
from intracellular storage sites to the plasma membrane. In
the basal state, GLUT-4 is localized to a morphologically
defined “tubulovesicular system” present in the intracellular
compartment, while in the presence of insulin, GLUT-4 is
immunolocalized to the plasma membrane of fat cells [138].
The rate-limiting step at which insulin stimulates uptake of
glucose in fat is the translocation of GLUT-4 to the plasma
membrane [139]. At least two discrete signalling pathways
have been implicated in insulin-regulated GLUT-4 transloca-
tion. The first involves the lipid kinase phosphatidylinositol
3-kinase (PI3K) [140, 141], and the second involves the
proto-oncoprotein c-Cbl [142, 143]. When insulin binds to
its receptor induces a conformational change in the receptor
and leads to activation of its tyrosine-kinase domain. On
activation, the receptor phosphorylates several proximal sub-
strates, including members of the IRS and c-Cbl. Tyrosine-
phosphorylated IRS proteins, which are thought to be
held in close proximity to the plasma membrane through
association with the underlying cytoskeleton, recruit more
eﬀectors molecules, such as PI3K, to this location. Two
important targets of PI3K in muscle and fat cells that have
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Figure 2: β-cell mechanisms of insulin release and its regulation by ghrelin. When the plasma glucose concentration rises, β-cells oxidize it.
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KATP-channels, depolarisation of the plasma membrane potential (Δψp) and Ca2+ flux into the cell, triggering insulin release. UCP2 activity
dissipates the protonmotive force, lowering ATP/ADP. Ghrelin directly acts on the β-cell and via PTX–sensitive mechanisms attenuates
glucose-induced [Ca2+]i signalling partly through enhancement of TEA-sensitive delayed outward K+ currents resulting in decrease plasma
insulin levels. PTX catalyzes the ADP-ribosylation of the α subunits of the heterotrimeric G proteins Gi, Go, and Gt. This prevents the G
proteins from interacting with G protein-coupled receptors on the cell membrane thus interfering with intracellular communication. Since
the Gα subunits remain in their GDP-bound, inactive state, they are unable to inhibit adenylyl cyclase, thus keeping levels of adenylyl cyclase
and cAMP elevated. PTX inhibited a number of insulin-stimulated cellular events, such as glucose transport and its metabolism. Antisense
oligonucleotide specific for Gαi2-subunit of G proteins blocks the eﬀects of ghrelin on [Ca2+]i and insulin release. Hence ghrelin presumably
suppresses glucose-induced insulin release via Gαi2- and Kv channel–mediated attenuation of Ca2+ signalling in β-cells.
been shown to have a role in insulin-stimulated GLUT-4
translocation are the AKT and the protein kinase C (PKC).
PI3K activates AKT by generating polyphosphoinositides in
the inner leaflet of the plasma membrane. This acts as an
anchorage site for AKT through its pleckstrin homology
domain, thereby bringing it in close proximity to its
upstream regulatory kinase, phosphatidylinositol-dependent
kinase-1 (PDK-1). The second putative signalling pathway
that has been shown to have a role in insulin-stimulated
GLUT-4 translocation operates independently of PI3K and
involves a dimeric complex that comprises c-Cbl and the
c-Cbl-associated protein CAP. Intriguingly, whereas many
growth factors trigger the activation of PI3K, AKT, and
PKC in many cell types, aspects of the c-Cbl–CAP pathway,
including the tyrosine phosphorylation and the expression
of CAP, seem to be unique to muscle and fat cells [144].
Patel et al. examined the expression of GHSR1a in discrete
adipose tissue depots and while GHSR1a expression was
detected in the epididymal and pericardial deposits, it was
not found in the perirenal, subcutaneous, and omental
deposits. Ghrelin and des-acyl ghrelin did not aﬀect basal
deoxyglucose uptake in adipocytes from the epididymal fat
deposits. However, treating isolated epididymal adipocytes
with ghrelin in the presence of insulin increased insulin-
stimulated deoxyglucose uptake. Des-acyl ghrelin had no
significant eﬀect on insulin-stimulated deoxyglucose uptake
in isolated epididymal adipocytes. Ghrelin had no eﬀect on
basal deoxyglucose uptake in isolated perirenal adipocytes,
which do not express the GHSR1a mRNA. As expected,
insulin increased glucose uptake, but ghrelin in the presence
of insulin did not further increase this response. Further-
more, des-acyl ghrelin did not increase insulin-stimulated
deoxyglucose uptake in perirenal adipocytes. These data
suggest that ghrelin may act synergistically to potentiate
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insulin-stimulated glucose uptake and may improve insulin
sensitivity [145]. Interestingly, ghrelin did not aﬀect insulin-
stimulated glucose uptake in perirenal adipocytes, which do
not express GHSR1a, and des-acyl ghrelin, which does not
bind to GHSR1a, did not influence insulin-stimulated glu-
cose uptake in epididymal adipocytes The eﬀects of ghrelin
on adipocyte glucose uptake might be expected to result in
fatty acid accumulation and an increase in adiposity in the
long term [145]. Kim and colleagues incubated terminally
diﬀerentiated 3T3-L1 adipocytes with insulin or/and ghrelin
overnight and assayed glucose transport. Insulin and ghrelin
increased glucose transport and the cotreatment of insulin
and ghrelin induced a further increase in glucose transport.
In addition, ghrelin treatment induced increases IRS-1 and
AKT phosphorylation, but when the adipocytes were treated
with wortmannin, a PI3K inhibitor, completely blocked this
ghrelin induced increase in glucose transport and phospho-
AKT expression [146], suggesting that PI3K/AKT activation
may mediate the eﬀect of ghrelin on glucose transport in
these adipocytes (Figure 3).
All these data suggest that the direct eﬀects of ghrelin
on insulin-stimulated glucose uptake are mediated by the
GHSR1a and PI3K/AKT activation.
5. Pharmacological Uses of Ghrelin on
Glucose-Insulin Homeostasis
Overt diabetes mellitus is defined clinically by fasting or
postprandial hyperglycemia or an abnormally increased
glucose excursion in response to a defined glucose load.
Insulin resistance, measured as impaired glucose disposal
in a hyperinsulinemic-euglycemic clamp study, is one of
the earliest detectable disorder and is considered a car-
dinal pathophysiologic feature [147]. Fasting hyperinsu-
linemia is also present early in the disease process and
is thought to be a compensatory mechanism to maintain
euglycemia in the setting of insulin resistance [148]. Even
while maintaining a healthy lifestyle, most patients need
pharmacological intervention which might consist of one or
a combination of the following oral medications: sulfony-
lureas, glinides, incretin mimetics, α-glucosidase inhibitors,
metformin, or thiazolidinediones. However 30%–40% of
patients are not adequately controlled by these therapies
and require subcutaneous insulin injections intended to
restore normoglycemia, but they can inadvertently lead
to hypoglycemia, a potentially fatal consequence. Thus,
new drugs and novel methods of treatment are needed.
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Table 7: Potential therapeutic uses of ghrelin agonists and antago-
nists on glucose-insulin homeostasis.
Ghrelin agonists Ghrelin antagonists
Insulinoma Type 2 Diabetes mellitus
Anorexia nervosa Metabolic syndrome
Cachexia of malignancy Obesity
Table 8: Summary of putative ghrelin eﬀect on glucose-insulin
homeostasis and related physiological actions.
Ghrelin eﬀects on glucose-insulin homeostasis
Increase glycemia
Decrease insulinemia
Increase food intake
Increase body weight and adiposity percentage
Increase GH secretion
Among diabetic patients, 10%–20% fall into the category
of insulin-dependent diabetes mellitus (IDDM) or type 1
diabetes, which generally appears before age 40, frequently
in adolescence, and results from autoimmune destruction
of insulin producing pancreatic β-cells. Type 1 diabetic
patients depend on insulin administration for their survival.
Noninsulin-dependent diabetes mellitus (NIDDM) or type 2
diabetes is far more common than IDDM, aﬀecting 80%–
90% of diabetic patients. The prevalence of obesity and
type 2 diabetes continues to increase at alarming rates
[149]. Type 2 diabetes is a prototypic complex, polygenic
disease with a strong heritable component, which is also
heavily influenced by environmental factors, especially diet
and physical activity. It appears that altered communication
among tissues and loss of the ability of tissues to adapt to
changing metabolic states play a critical role in the altered
glucose homeostasis that leads to the development of type
2 diabetes. It is characterized by a combination of factors
that aﬀect the organism’s ability to respond to insulin. The
condition has two hallmark features: (1) insulin resistance
and (2) compromised function of the pancreatic β-cell, such
that insulin secretion is insuﬃcient to counterpart the degree
of insulin resistance. There is general agreement that type
2 diabetes, unlike IDDM, is tightly associated with obesity.
Over 80% of individuals with type 2 diabetes are obese.
However, only 10% of obese individuals are diabetic. In the
prediabetic phase, when insulin resistance has already begun,
the β-cell actually hypersecretes insulin despite normal blood
glucose levels. What has defied explanation is precisely
what causes this insulin resistance in the first place and
how it relates in a temporal sense to the accompanying
hyperinsulinemia.
Ghrelin receptor modulation could be clinically useful
for diﬀerent situations related with glucose-insulin home-
ostasis (Table 7). Several works demonstrated that ghrelin
concentrations are negatively associated with fasting insulin
levels, the prevalence of type 2 diabetes and insulin resistance
in humans, regardless of race [102, 150, 151]. The data
obtained since ghrelin discovery show that both the acylated
and unacylated molecules are actively involved in the acute
and long-term control of glucose metabolism and insulin
sensitivity in humans, which might enable new treatment
modalities for the many disorders in which insulin sensitivity
is disturbed. Thus, pharmacological, immunological, and
genetic blockade of ghrelin or ghrelin action in pancreatic
islets all markedly enhanced glucose-induced insulin release
and improve the diabetic condition. Hence ghrelin inhi-
bition could be useful for the treatment of diabetes [152,
153].
On the other hand the ability to eﬃciently build fat
reserves in times of nutritional abundance appears to have
resulted from evolutionary pressure to protect against sub-
sequent periods of food scarcity. The tendency to eﬃciently
store fat in times of caloric excess appears to have become
paradoxically maladaptive in settings of continuous food
availability, as indicated by the present epidemic of obesity
in Western societies. The data obtained in the last years
seem to indicate that ghrelin may be one of the primary
mechanisms by which an individual can sense changes in
nutrient availability and trigger biological responses that
modulate the eﬃciency of energy storage (and particularly
fat deposition) during periods of fuel overflow or after
a period of scarcity of nutrients. At present, ghrelin is
the only peripheral orexigenic factor that is eﬀective upon
its intravenous administration [81]. Put in this context,
the blockade of the route of ghrelin could prove useful
in controlling adiposity in human obesity, as blockers of
the orexigenic signal from the gastrointestinal tract to
the brain, or diminishing the ability to eﬃciently store
fat reserves. Inverse agonists of the ghrelin receptor, by
blocking the constitutive receptor activity, might lower the
set-point for hunger between meals [110, 154]. All these
data suggest that ghrelin-ghrelin receptor modulation has the
potential to improve the diabetic condition by promoting
glucose-dependent insulin secretion and promoting weight
loss.
In contrast, ghrelin may be useful as an orexigenic
agent for the treatment of eating disorders such as anorexia
nervosa. Administration of ghrelin can stimulate appetite
and improve the nutritional status of these patients. How-
ever, plasma ghrelin concentrations in anorexia nervosa
are high, indicating a situation of ghrelin resistance [100].
In fact, circulating ghrelin levels have been found altered
in diﬀerent clinical situations, like renal failure or hepatic
failure [101, 155]. Ghrelin-derived drugs could also be
useful in all the clinical situations associated with cachexia,
such as malignancy, advanced cardiac failure, renal failure,
postoperative patients, and human immunodeficiency virus-
lipodystrophy. In Table 8 we summarize putative ghrelin
eﬀects on glucose-insulin homeostasis and related physiolog-
ical actions.
In summary, there are multiple studies suggesting that
ghrelin could have an important function in glucose home-
ostasis and insulin release and probably insulin action. At
least theoretically ghrelin and/or its signalling manipulation
could be used for the treatment or prevention of diseases of
glucose homeostasis such as type 2 diabetes.
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